ClinicalTrials.gg
RecruitingNCT07453004Updated Oct 15, 2026

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

A Phase 2 interventional study of Plonmarlimab and Compound betamethasone in Acute Gouty Arthritis, sponsored by TJ Biopharma Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by TJ Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 15, 202629 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Arthritis, Gouty with a site in China — 5 open to participants now, 6 under way, none of them phase 3. Arthritis, Gouty · China.

Planned enrollment
3rd of 10
170 · median 134
Started
2026
with 2 others
Phase 2
5 of 11
3 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
TJ Biopharma Co., Ltd.

Among the 11 studies in Arthritis, Gouty with a site in China, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 9th registered.

Arthritis, Gouty

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

Browse Arthritis, Gouty studies →

Open to participants now

5 of the 11 studies in Arthritis, Gouty with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Arthritis, Gouty with a site in China, or all of them as a file.
02

Study summary

This is a multi center,randomized,double-blind,double-dummy,active-controlled study,and planned enrollment of 120-170 subjects,an interim analysis will be conducted after first 60 subjects complete the 72 -hour pain Visual Analogue Scale(VAS) assessment following their initial dose.Based on the analysis result,the sample size may be adjusted, and 1or 2 group(s)of the investigational drug will be selected to continue enrollment along with the active comparator group.The goal is to evaluate the efficacy of plonmarlimab in subjects with acute gouty arthristis.

03

Conditions studied

  • Acute Gouty Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged ≥18 years, regardless of gender.
  • Subjects are willing to participate in this study and voluntarily sign the form.
  • Meet the 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) gout classification criteria.
  • Experienced ≥3 episodes of acute gout flare within the 12 months prior to baseline (determination of an acute gout flare based on patient history, referral records, etc., will be made by the investigator).
  • Subjects have experienced an acute gout flare within 5 days prior to administration of the product (determination of an acute gout flare based on patient history, referral records, etc., will be made by the investigator).
  • , intolerant, or inadequately responsive to colchicine and/or non-steroidal anti-inflammatory drugs (NSAIDs) (determination based on patient history, referral records, etc., will be made by the investigator).
  • Baseline pain intensity assessment in the most severely affected joint by the subject using a 0-100 mm Visual Analogue Scale (VAS) is ≥50 mm.
  • Subjects may or may not be receiving urate-lowering therapy. If planning to continue urate-lowering therapy during the study, it must have been at a stable dose for ≥2 weeks prior to baseline.
  • Subjects (including their partners) have no pregnancy plans from the screening period until 90 days after dosing and voluntarily agree to use effective .

Exclusion criteria

Exclusion Criteria:

  • Secondary gout caused by various etiologies (e.g., gout induced by chemotherapy, judged by the investigator based on the subject's medical history, referral records, etc.).
  • History of to any component of the product or to similar biological agents.
  • to compound betamethasone therapy.
  • Presence of other rheumatic diseases besides gout that may interfere with interpretation of results, including but not limited to rheumatoid arthritis, infectious/suppurative arthritis, traumatic arthritis, etc.
  • Pulmonary diseases including but not limited to asthma, , interstitial lung disease, pulmonary alveolar proteinosis, pulmonary granulomatosis, etc., or any underlying pulmonary disease that significantly impairs pulmonary function as assessed by the investigator, making the subject unsuitable for this clinical study.
  • Cardiovascular diseases: history of acute myocardial infarction, unstable angina, severe arrhythmia (multifrequent premature ventricular contractions, ventricular tachycardia, ventricular fibrillation) within the past 6 months; (NYHA) functional Class III-IV (see Appendix 4). Presence of long syndrome or QTc interval > 450 msec (male) or > 470 msec (female) during screening.
  • History of within the past 5 years (regardless of treatment), except for successfully treated basal cell or squamous cell carcinoma of the skin.
  • Other diseases: subjects with a past and/or current , unstable, or uncontrolled acute or chronic disease unrelated to gout (e.g., acute pneumonia, pulmonary hypertension, diabetic ketoacidosis, acute pancreatitis, etc.), or scheduled medical/surgical procedures; or any condition that places the subject at undue risk or impairs the ability to participate voluntarily.
  • Infections: presence of any known acute, chronic, or recurrent active infection during screening (e.g., tuberculosis, syphilis, , , , Pneumocystis jirovecii, CMV, HSV, VZV, atypical mycobacteria, Histoplasma capsulatum, Salmonella infection, genital herpes, osteomyelitis, urinary tract infection, etc.).
  • Abnormal hepatic and renal function: (AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) > 2 × (ULN); alkaline phosphatase (ALP) or total (TBIL) > 1.5 × ULN; creatinine (Cr) or blood urea nitrogen (BUN) > 1.5 × ULN; or ≤ 60 mL/min/1.73 m² prior to screening (calculated using the MDRD formula, see Appendix 9).
  • Hematological diseases or abnormal routine blood tests: subjects with a past or current hematological disease including but not limited to myelofibrosis, aplastic anemia, leukemia, lymphoma, etc.; \< 90 g/L, count \< 80×10⁹/L, white blood cell or below the lower limit of normal with clinically significant abnormality judged by the investigator.
  • Planned surgery or any other medical history (e.g., recent sepsis), laboratory abnormality, or other condition judged by the investigator to render the subject ineligible for this study.
  • History of organ transplantation.
  • Pregnant or lactating female subjects.
  • Participation in any interventional clinical trial (including investigational vaccines) or use of an invasive investigational medical device within 3 months prior to enrollment, or current enrollment in another interventional study.
  • Administration of live (attenuated) vaccine within 30 days prior to screening. Inability to receive intramuscular injection (e.g., subjects on anticoagulants, thrombocytopenia, known bleeding disorders such as idiopathic thrombocytopenic purpura).
  • Drug abuse detected by urine drug screening, including morphine, ketamine, tetrahydrocannabinol, methamphetamine, MDMA, cocaine.
  • Alcohol abuse within 3 months prior to screening, defined as alcohol consumption > 14 units per week (1 unit = 17.5 mL or 14 g pure alcohol; 1 unit ≈ 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or alcohol-containing products during the trial.
  • Any other condition deemed by the investigator to render the subject unsuitable for this clinical study, including any condition that may increase study-related risk, interfere with evaluation of the investigational product, or confound interpretation of study results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Group1-Plonmarlimab 3mg/kg

    Plonmarlimab 3mg/kg, Single dose, Intravenous infusion

    Drug: Plonmarlimab · Drug: Compound betamethasone placebo

  • Experimental
    Group2-Plonmarlimab 6mg/kg

    Plonmarlimab 6mg/kg, Single dose, Intravenous infusion

    Drug: Plonmarlimab · Drug: Compound betamethasone placebo

  • Active comparator
    Group3-Compound betamethasone

    Compound betamethasone 7 mg, single dose, intramuscular injection

    Drug: Compound betamethasone · Drug: Plonmarlimab placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale(VAS) score

    The change from baseline in the subject's self-assessed Visual Analogue Scale (VAS) score for pain intensity in the most severely affected joint at baseline, assessed at 72 hours after the initial dose.

    Time frame: 72 hours after the initial dose.

07

Study locations

1 of 30 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
    Not yet recruiting
    • Yongjun Mei · Contact
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Not yet recruiting
    • Lin Tang · Contact
  • Jiangmen Central Hospital
    Jiangmen, Guangdong, China
    Not yet recruiting
    • Mingliang Feng · Contact
  • Zhongshan Hospital of Traditional Chinese Medicine
    Zhongshan, Guangdong, China
    Not yet recruiting
    • Yanlin Li · Contact
  • The first affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
    Not yet recruiting
    • Yuhong Shi · Contact
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Not yet recruiting
    • Fang Tan · Contact
  • The Second Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Not yet recruiting
    • Cundong Mi · Contact
  • Hebei Petro China Central Hospital
    Langfang, Hebei, China
    Not yet recruiting
    • Wei Gou · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Not yet recruiting
    • Zhanqing Gu · Contact
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Not yet recruiting
    • Xiaofei Shi · Contact
  • Zhengzhou Central Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Lei Yang · Contact
  • UnHospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Rong Du · Contact
  • The central Hospital of Xiangtan
    Xiangtan, Hunan, China
    Not yet recruiting
    • Yong Tan · Contact
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan, China
    Not yet recruiting
    • Zhenhua Wen · Contact
  • Wuxi People's Hospital
    Wuxi, Jiangsu, China
    Not yet recruiting
    • Fenghong Yuan · Contact
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu, China
    Not yet recruiting
    • Hua Wei · Contact
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi, China
    Not yet recruiting
    • Rongping Li · Contact
  • PingXiang People's Hospital
    Pingxiang, Jiangxi, China
    Not yet recruiting
    • Senhua Dai · Contact
  • The People's Hospital of Jilin Province
    Changchun, Jilin, China
    Not yet recruiting
    • Guoping Jiang · Contact
  • Shandong Medical and Pharmaceutical University Hospital
    Binzhou, Shandong, China
    Not yet recruiting
    • Xuebin Wang · Contact
  • Jining NO.1 People's Hospital
    Jining, Shandong, China
    Not yet recruiting
    • Shujie Li · Contact
  • Linyi People Hospital
    Linyi, Shandong, China
    Not yet recruiting
    • Li Jiang · Contact
  • Zaozhuang Municipal Hospital
    Zaozhuang, Shandong, China
    Not yet recruiting
    • Hua Zhang · Contact
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Chunde Bao · Contact
    • Qiong Fu · Contact
  • Linfen Central Hospital
    Linfen, Shanxi, China
    Not yet recruiting
    • Shuhua Qiang · Contact
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
    Not yet recruiting
    • Liyun Zhang · Contact
  • Chengdu fifth People's Hospital
    Chengdu, Sichuan, China
    Not yet recruiting
    • Yong Zhu · Contact
  • Mianyang Central Hospital
    Mianyang, Sichuan, China
    Not yet recruiting
    • Jinmei Zou · Contact
  • The first People's Hospital of Yibin
    Yibin, Sichuan, China
    Not yet recruiting
    • Jiangtao Li · Contact
  • Huzhou Third People's Hospital
    Huzhou, Zhejiang, China
    Not yet recruiting
    • Xiaobing Yang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 5, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
29 sites added
Show 29 added (29 China)
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
  • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
  • Jiangmen Central Hospital · Jiangmen, China
  • Zhongshan Hospital of Traditional Chinese Medicine · Zhongshan, China
  • The first affiliated Hospital of Guilin Medical University · Guilin, China
  • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
  • The Second Affiliated Hospital of Guangxi Medical University · Nanning, China
  • Hebei Petro China Central Hospital · Langfang, China
  • The First Hospital of Hebei Medical University · Shijiazhuang, China
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • Zhengzhou Central Hospital · Zhengzhou, China
  • UnHospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • The central Hospital of Xiangtan · Xiangtan, China
  • Zhuzhou Central Hospital · Zhuzhou, China
  • Wuxi People's Hospital · Wuxi, China
  • Northern Jiangsu People's Hospital · Yangzhou, China
  • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
  • PingXiang People's Hospital · Pingxiang, China
  • The People's Hospital of Jilin Province · Changchun, China
  • Shandong Medical and Pharmaceutical University Hospital · Binzhou, China
  • Jining NO.1 People's Hospital · Jining, China
  • Linyi People Hospital · Linyi, China
  • Zaozhuang Municipal Hospital · Zaozhuang, China
  • Linfen Central Hospital · Linfen, China
  • Shanxi Bethune Hospital · Taiyuan, China
  • Chengdu fifth People's Hospital · Chengdu, China
  • Mianyang Central Hospital · Mianyang, China
  • The first People's Hospital of Yibin · Yibin, China
  • Huzhou Third People's Hospital · Huzhou, China
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    29 sites added
    Show 29 added (29 China)
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
    • The Second Affiliated Hospital of Chongqing Medical University · Chongqing, China
    • Jiangmen Central Hospital · Jiangmen, China
    • Zhongshan Hospital of Traditional Chinese Medicine · Zhongshan, China
    • The first affiliated Hospital of Guilin Medical University · Guilin, China
    • The First Affiliated Hospital of Guangxi Medical University · Nanning, China
    • The Second Affiliated Hospital of Guangxi Medical University · Nanning, China
    • Hebei Petro China Central Hospital · Langfang, China
    • The First Hospital of Hebei Medical University · Shijiazhuang, China
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • Zhengzhou Central Hospital · Zhengzhou, China
    • UnHospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • The central Hospital of Xiangtan · Xiangtan, China
    • Zhuzhou Central Hospital · Zhuzhou, China
    • Wuxi People's Hospital · Wuxi, China
    • Northern Jiangsu People's Hospital · Yangzhou, China
    • First Affiliated Hospital of Gannan Medical University · Ganzhou, China
    • PingXiang People's Hospital · Pingxiang, China
    • The People's Hospital of Jilin Province · Changchun, China
    • Shandong Medical and Pharmaceutical University Hospital · Binzhou, China
    • Jining NO.1 People's Hospital · Jining, China
    • Linyi People Hospital · Linyi, China
    • Zaozhuang Municipal Hospital · Zaozhuang, China
    • Linfen Central Hospital · Linfen, China
    • Shanxi Bethune Hospital · Taiyuan, China
    • Chengdu fifth People's Hospital · Chengdu, China
    • Mianyang Central Hospital · Mianyang, China
    • The first People's Hospital of Yibin · Yibin, China
    • Huzhou Third People's Hospital · Huzhou, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07453004
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Mar 26, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Lina Qin
Contact
lina.qin@tjbio.com
18600672907

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plonmarlimab

Start the discussion